The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes: The STOP-NIDDM trial

Journal of Internal Medicine

Volumn 257, Issue 2, 2005, Pages 185-193

  Zacharova, J ^a   Todorova, B R ^a   Chiasson, J L ^b   Laakso, M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

G 250A polymorphism; Hepatic lipase gene; Impaired glucose tolerance; STOP NIDDM; Type 2 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; GENE CONTROL; GENOTYPE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPC GENE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; LIPASE; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 13244279651     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01435.x     Document Type: Article

References (39)

1. Perret B, Mabile L, Martinez L, Terce F, Barbaras R, Collet X. Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res 2002; 43: 1163-9.
2. Jansen H, van Tol A, Hulsmann WC. On the metabolic function of heparin-releasable liver lipase. Biochem Biophys Res Commun 1980; 92: 53-9.
3. Jensen GL, Daggy B, Bensadoun A. Triacylglycerol lipase, monoacylglycerol lipase and phospholipase activities of highly purified rat hepatic lipase. Biochim Biophys Acta 1982: 710: 464-70.
4. Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol 2000; 11: 277-83.
5. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 2003; 44: 1279-86.
6. Santamarina-Fojo S, Haudenschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1998; 9: 211-9.
7. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998; 18: 1723.
8. Grundy SM, Vega GL, Otvos JD, Rainwater DL, Cohen JC. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence. J Lipid Res 1999; 40: 229-34.
9. Kuusi T, Saarinen P, Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. Atherosclerosis 1980; 36: 589-93.
10. Su Z, Zhang S, Nebert DW et al. A novel allele in the promoter of the hepatic lipase is associated with increased concentration of HDL-C and decreased promoter activity. J Lipid Res 2002; 43: 1595-601.
11. Carr MC, Hokanson JE, Zambon A et al. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab 2001; 86: 2831-7.
12. Nie L, Wang J, Clark LT et al. Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res 1998; 39: 1127-30.
13. Jansen H, Verhoeven AJ, Weeks L et al. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 1997; 17: 2837-42.
14. van't Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A. Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Arterioscler Thromh Vasc Biol 2000; 20: 1335-9.
15. Vega GL, Clark LT, Tang A, Marcovina S, Grundy SM, Cohen JC. Hepatic lipase activity is lower in African American men than in white American men: effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res 1998; 39: 228-32.
16. Pihlajamaki J, Karjalainen L, Karhapaa P et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2000; 20: 1789-95.
17. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999; 144: 285-301.
18. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1-12.
19. Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553-9.
20. Todorova B, Kubaszek A, Pihlajamaki J et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004; 89: 2019-23.
21. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
22. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to prevent non-insulin-dependent diabetes mellitus. Diabetes Care 1998; 21: 1720-5.
23. Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985; 727: 1-113.
24. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000; 43: 1507-11.
25. Dugi KA, Brandauer K, Schmidt N et al. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation 2001; 104: 3057-62.
26. Jansen H, Waterworth DM, Nicaud V, Ehnholm C, Talmud PJ. Interaction of the common apolipoprotein C-III (APOC3 - 482C > T) and hepatic lipase (LIPC -514C > T) promoter variants affects glucose tolerance in young adults. European Atherosclerosis Research Study II (EARS-11). Ann Hum Genet 2001; 65: 237-43.
27. Deeb SS, Peng R. The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000; 41: 155-8.
28. Guerra R, Wang J, Grundy SM, Cohen JC. A hepatic lipase (LFPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 1997; 94: 4532-7.
29. Hokanson JE, Cheng S, Snell-Bergeon JK et al. A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes. Diabetes 2002; 51: 1208-13.
30. Zambon A, Deeb SS, Brown G, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 2001; 103: 792-8.
31. Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease. J Am Coll Cardiol 2003; 41: 1972-82.
32. Santamaria-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1750-4.
33. Machicao F, Staiger H, Fritsche A et al. Association of the - 514C->T polymorphism in the hepatic lipase gene (LIPC) promoter with elevated fasting insulin concentrations, but not insulin resistance, in non-diabetic Germans. Horm Metab Res 2004; 36: 303-6.
34. Ordovas JM, Corella D, Demissie S et al. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Circulation 2002; 106: 2315-21.
35. Tai ES, Corella D, Deurenberg-Yap M et al. Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: the 1998 Singapore National Health Survey. J Nutr 2003; 133: 3399-408.
36. Lindstrom J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-6.
37. Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res 2002; 43: 383-91.
38. Yamakawa-Kobayashi K, Somekawa Y, Fujimura M, Tomura S, Arinami T, Hamaguchi H. Relation of the -514C/T polymorphism in the hepatic lipase gene to serum HDL and LDL cholesterol levels in postmenopausal women under hormone replacement therapy. Atherosclerosis 2002; 162: 17-21.
39. Baynes C, Henderson AD, Anyaoku V et al. The role of insulin insensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes. Diabet Med 1991; 8: 560-6.